A Meta-analysis of the Risk of Adverse Cardiovascular Events in Patients with Cancer Treated with Inhibitors of the PI3K/AKT/mTOR Signaling Pathway
- 9 November 2024
- journal article
- research article
- Published by Springer Nature in Cardiovascular Toxicology
- Vol. 25 (2) , 269-281
Abstract
No abstract availableKeywords
All Related Versions
This publication has 52 references indexed in Scilit:
- Inhibitors of the PI3K/AKT/mTOR pathway in human malignancies; trend of current clinical trialsJournal of Cancer Research and Clinical Oncology, 2023
- Incidence of Cutaneous Adverse Events With Phosphoinositide 3-Kinase Inhibitors as Adjuvant Therapy in Patients With CancerJAMA Oncology, 2022
- Comparative efficacy of amitriptyline, duloxetine and pregabalin for treating fibromyalgia in adults: an overview with network meta-analysisClinical Rheumatology, 2022
- Factors leading to alpelisib discontinuation in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative breast cancerBreast Cancer Research and Treatment, 2022
- Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 studyAmerican Journal of Hematology, 2019
- mTOR Signaling pathway as a master regulator of memory CD8+ T‐cells, Th17, and NK cells development and their functional propertiesJournal of Cellular Physiology, 2019
- Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial ProtocolsJAMA, 2018
- Trastuzumab containing regimens for early breast cancerCochrane Database of Systematic Reviews, 2012
- Phase 1/2 study of everolimus in advanced hepatocellular carcinomaCancer, 2011
- Much ado about nothing: a comparison of the performance of meta‐analytical methods with rare eventsStatistics in Medicine, 2006